Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
Retroperitoneal fibrosis (RPF) is an uncommon disorder that may cause ureteric obstruction with renal damage. Pergolide, a dopaminergic agonist used in the treatment of Parkinson's disease, has rarely been related to the development of RPF. We report on a 78-year-old woman with Parkinson's disease who presented with hydroureteronephrosis and developed RPF and serosal fibrosis during treatment with pergolide. Following discontinuation of pergolide therapy and placement of a double-J stent, her renal function improved. Inflammatory markers returned to normal limits within two months and the retroperitoneal fibrotic mass became smaller.
Bilici
A
A
Department of Internal Medicine, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey. ahmetknower@softhome.net
Karadag
B
B
Doventas
A
A
Erdincler
D Suna
DS
Cetinkaya
S
S
Ogut
G
G
Tezcan
V
V
Beger
T
T
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced*
D000978:Antiparkinson Agents; D010479:Pergolide